Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-α in dacarbazine-resistant malignant melanoma

Tumori

Volumn 84, Issue 1, 1998, Pages 48-51

  Bajetta, Emilio ^a   Rimassa, Lorenza ^a   Carnaghi, Carlo ^a   Del Vecchio, Michele ^a   Celio, Luigi ^a   Cassata, Antonio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cisplatin; Glatathione; Interferon ; Melanoma

Indexed keywords

ALPHA INTERFERON; AMIFOSTINE; CISPLATIN; DACARBAZINE; GLUTATHIONE;

ADULT; AGED; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA;

EID: 0031953702     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089169808400110     Document Type: Article

References (19)

1. Atzpodien J., Lopez Hänninen E., Kirchner H., Franzke A., Koerfer A., Volkenandt M., Duensing S., Schomburg A., Chaitchik S., Poliwoda H.: Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur. J. Cancer, 31A: 876-881, 1995.
2. Bajetta E., Di Leo A., Zampino M.G., Sertoli M.R., Comella G., Barduagni M., Giannotti B., Queirolo P., Tribbia G., Bernengo M.G., Menichetti E.T., Palmeri S., Russo A., Cristofolini M., Erbazzi A., Fowst C., Criscuolo D., Bufalino R., Zilembo N., Cascinelli N.: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J. Clin. Oncol., 12: 806-811, 1994.
3. Biological response modifiers in melanoma (B.Re.M.I.M.) Italian cooperative group.: Phase II study of interferon alpha-2A and dacarbazine in advanced melanoma. Eur. J. Cancer, 28: 1719-1720, 1992.
4. Buzaid A.C., Murren J., Durivage H.J.: High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. Am. J. Clin. Oncol., 14: 203-207, 1991.
5. Cascinu S., Cordella L., Del Ferro E., Fronzoni M., Catalano G.: Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J. Clin. Oncol., 13: 26-32, 1995.
6. Cole B.F., Gelber R.D., Kirkwood J.M., Goldhirsch A., Barylak E., Borden E.: Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J. Clin. Oncol., 14: 2666-2673, 1996.
7. Davol P.A., Goulette F.A., Frackelton A.R. Jr., Darnowski J.W.: Modulation of p53 expression by human recombinant interferon-α 2a correlates with abrogation of cisplatin resistance in a human melanoma cell line. Cancer Res., 56: 2522-2526, 1996.
8. Di Re F., Bohm S., Oriana S., Spatti G.B., Pirovano C., Tedeschi M., Zunino F.: High dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann. Oncol., 4: 55-61, 1993.
9. Franceschi S., La Vecchia C., Lucchini F., Cristofolini M.: The epidemiology of cutaneous malignant melanoma: aetiology and European data. Eur. J. Cancer Prev., 1: 9-22, 1991.
10. Glover D., Glick J.H., Weiler C., Fox K., Guerry D.: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J. Clin. Oncol., 5: 574-578, 1987.
11. Khayat D., Borel C., Tourani J.M., Benhammouda A., Antoine E., Rixe O., Vuillemine E., Bazek P.A., Thill L., Franks R., Auclerc G., Soubrane C., Banzet P., Weil M.: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon-α 2a for metastatic melanoma. J. Clin. Oncol., 11: 2173-2180, 1993.
12. Legha S.S., Papadopoulos N.E., Plager C., Ring S., Chawla S.P., Evans L.M., Benjamin R.S.: Clinical evaluation of recombinant interferon-α 2A (Roferon-A) in metastatic melanoma using two different schedules. J. Clin. Oncol., 5: 1240-1246, 1987.
13. Miller A.B., Hoogstraten B., Staquet M., Winkler A.: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
14. Rigel D.S., Friedman R.J., Kopf A.W.: The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatol., 34: 839-847, 1996.
15. Simon R.: Optimal two-stage design for phase II clinical trials. Controlled Clinical Trials, 10: 1-10, 1989.
16. Smyth J., Bowman A., Perren T., Wilkinson P., Prescott R., Quinn K., Tedeschi M.: Glutathione improves the therapeutic index of cisplatin and quality of life for patients with ovarian cancer. Proc. Am. Soc. Clin. Oncol., 14: 273 (Abstract n. 761), 1995.
17. Steis R.G., Smith J.W., Urba W.J., Clark J.W., Itri L.M., Evans L.M., Schoemberger C., Longo D.L.: Resistance to recombinant interferon alpha-2a in hairy cell leukemia associated with neutralizing anti-interferon antibodies. N. Engl. J. Med., 318: 1409-1413, 1988.
18. Trotta P.P.: Preclinical biology of alpha interferons. Semin. Oncol., 13 (suppl): 3-12, 1986.
19. Wittes R.E. (Ed.): Appendix A Grading of toxicity. In: Manual of Oncologic Therapeutics, pp. 627-632, Lippincott, Philadelphia, 1989.